Investigation of the Cylex® ImmuKnow® Assay

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00569842

Enrollment

Registered

2007-12-07

Start date

2007-11-30

Completion date

2012-12-31

Last updated

2014-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Hodgkin's Disease, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Non-Hodgkin's Lymphoma

Brief summary

Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible: 1. Acute leukemia 2. Non-Hodgkin's Lymphoma 3. Chronic lymphocytic leukemia 4. Hodgkin's disease 5. Multiple myeloma 6. Myelodysplastic Syndromes 7. Myeloproliferative Disorders 8. Aplastic Anemia 9. Chronic myelogenous leukemia

Countries

United States

Outcome results